Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice.
Liver fibrosis is characterized by excessive deposition of extracellular matrix in the liver during chronic injury. During early stages of this disease, cells begin to synthesize and secrete profibrotic proteins that stimulate matrix production and inhibit matrix degradation. Although it is clear that these proteins are important for development of fibrosis, what remains unknown is the mechanism by which chronic liver injury stimulates their production. In the present study, the hypothesis was tested that hypoxia-inducible factor-1alpha (HIF-1alpha) is activated in the liver during chronic injury and regulates expression of profibrotic proteins. To investigate this hypothesis, mice were subjected to bile duct ligation (BDL), an animal model of liver fibrosis. HIF-1alpha protein was increased in the livers of mice subjected to BDL by 3 days after surgery. To test the hypothesis that HIF-1alpha is required for the development of fibrosis, control and HIF-1alpha-deficient mice were subjected to BDL. Levels of type I collagen and alpha-smooth muscle actin mRNA and protein were increased in control mice by 14 days after BDL. These levels were significantly reduced in HIF-1alpha-deficient mice. Next, the levels of several profibrotic mediators were measured to elucidate the mechanism by which HIF-1alpha promotes liver fibrosis. Platelet-derived growth factor (PDGF)-A, PDGF-B, and plasminogen activator inhibitor-1 mRNA levels were increased to a greater extent in control mice subjected to BDL compared with HIF-1alpha-deficient mice at 7 and 14 days after BDL. Results from these studies suggest that HIF-1alpha is a critical regulator of profibrotic mediator production during the development of liver fibrosis.
Moon
Jeon-Ok
JO
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, 4063 KLSIC, 3901 Rainbow Blvd., Kansas City, KS 66160, USA.
Welch
Timothy P
TP
Gonzalez
Frank J
FJ
Copple
Bryan L
BL
D000199:Actins / Q000378:metabolism; D000818:Animals; D001652:Bile Ducts; D002455:Cell Division / Q000502:physiology; D001651:Cholestasis, Extrahepatic / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology*; D024042:Collagen Type I / Q000378:metabolism; D004195:Disease Models, Animal; D016222:Fibroblast Growth Factor 2 / Q000235:genetics; D015870:Gene Expression / Q000502:physiology; D000860:Hypoxia / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics* / Q000378:metabolism; D008026:Ligation; D008103:Liver Cirrhosis / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D010982:Platelet-Derived Growth Factor / Q000235:genetics; D058258:Serpin E2; D015843:Serpins / Q000235:genetics
D000199:Actins; D024042:Collagen Type I; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D010982:Platelet-Derived Growth Factor; D058258:Serpin E2; C511869:Serpine2 protein, mouse; D015843:Serpins; D016222:Fibroblast Growth Factor 2